8Kuznetsova MA,Vaulin NA,Masenko VP,et al.Non-ST-elevation acute coronary syndrome.Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation[J].Kardiologiia,2010;50(2):21-5.
4Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广（译）,王淑敏（译）,胡大一（校）.极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志（中文版）,2006,25(4):215-223. 被引量：349
7Costa MA,Simon DI.Molecular basis of restenosis and drug-eluting stents[J].Cireulation,2005,111(17):2257-2273.
8Grewe PH,Deneke T,Machraoui A,et al.Acute and chronic tissue response to coronary stent implantation:pathologic findings in human specimen[J].J Am Coll Cardiol,2000,35(1):157-163.
9Hong YJ,Jeong MH,Lim SY,et al.Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of instent restenosis after successful coronary artery stenting[J].Am J Cardiol,2006.98(3):341-345.
10Bayes-Genis A,Schwartz RS,Lewis DA,et al.Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty[J].Arterioscler Thromb Vasc Biol,2001,21(3):335-341.
2Sardella G,Lucisano L,Mancone M,et al.Comparison of high relo- ading Rosuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial[J].Int J Cardiol,2013, 168(4):3715-3720.
3Bertrand OF, B lisle P, Joyal D,et al. Comparison of transradial and femoral approaches for percutaneous coronary interventions: a sys- tematic review and hierarchical Bayesian meta- analysis [ J ]. Am Heart J,2012,163(4) :632 -648.
4Olsen S,Nielsen J. A study into postoperative urine retention in the re- covery ward[ J ]. Brit J of Anaesth & Recov Nuts ,2007,8(4) :91-95.
6Farnier M,Ducobu J,Bryniarski L.Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy[J].Am J Cardiol,2010;106(6):787-92.
